Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narlaprevir/Ritonavir + Daclatasvir in HCV Genotype 1b
NCT03485846Phase 2Completed
- Sponsor
- R-Pharm
- Start
- Nov 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of narlaprevir in hepatitis C (HCV), sponsored by R-Pharm. Started Nov 2017; status: completed.
02
Drugs
narlaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03485846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485846.